Up 10%: Why the Polynovo share price is popping today

Polynovo shares are rocketing for the second day in a row…

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's looking like another strong day for ASX shares and the S&P/ASX 200 Index (ASX: XJO) so far this Tuesday. At the time of writing, the ASX 200 has gained a healthy 0.38%, putting the index back over 7,500 points. But let's discuss the Polynovo Ltd (ASX: PNV) share price.

Polynovo shares are putting the gains of the broader market to shame so far this Tuesday. At present, the ASX 200 healthcare stock is up a whopping 8.16% at $1.88 a share. That's after Polynovo stock lifted as high as $1.92 soon after market open this morning (up more than 10% at the time).

So what's going on with this healthcare company today that is resulting in these kinds of stellar share price moves?

Polynovo shares spike 10% on bumper trading result

It seems that these gains can be put down to the trading update Polynovo released yesterday during trading hours.

As we briefly touched on yesterday afternoon, this indicative trading update (covering the first half of FY2024) was probably responsible for Polynovo shares' near-10% rise for Monday's session.

It's not too hard to see why.

Polynovo told investors that its total global revenue for the first half of FY2024 came in at 48.8 million, up 65.6% from the $29.5 million recorded at this time last year.

The company also achieved a record sales revenue of $42.2 million (up 54.9%), as well as U.S. sales of $32.2 million (up 41.7%).

Rest of world sales rocketed 122.2% to $10 million.

The company also reported positive earnings before interest, tax, depreciation and amortisation (EBITDA), and a net profit after tax (NPAT) for the period. Excluding non-cash items, Polynovo achieved an underlying EBITS of $3.6 million for the period.

Polynovo chair David Williams had this to say on these numbers:

While I view profit as a 'nice to have', I am more excited by the significant near-term revenue growth possibilities from our expanding geographic footprint and the new ways surgeons have found to use our products. Profits will drop naturally out of the drive and success in expanding our geographies and products.

Given most of yesterday's strong share price gains came after Polynovo released this update, it seems that we can thank it for both those gains, and the further rise we are seeing today.

But despite these gains, the Polynovo share price remains down by 25.8% over the past 12 months.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Telix shares fall despite 'significant milestone'

Let's see what the biotech has announced on Monday.

Read more »

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Healthcare Shares

Here's the earnings forecast out to 2030 for CSL shares

How healthy will the profit growth be in the coming years?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

After soaring 40% in 2 weeks, this ASX All Ords healthcare stock has been downgraded

Here’s what analysts at Macquarie rate the stock as now.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Own NIB shares? Here are the key dates for 2026

NIB has released its corporate calendar, including dividend dates, for 2026.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

ASX healthcare stock debuts at a massive discount to its initial public offer price

Saluda Medical shares have had a difficult start to public life, trading well below the initial public offer price.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Healthcare Shares

Why CSL shares now look 'massively oversold'

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which junior biotech's shares are flying on positive trial news?

This company's shares have surged higher after positive clinical trial results for its stroke treatment drug.

Read more »